Christopher Goetz to Carbidopa
This is a "connection" page, showing publications Christopher Goetz has written about Carbidopa.
Connection Strength
1.017
-
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan; 11(1):24-6.
Score: 0.133
-
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology. 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3.
Score: 0.087
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Score: 0.085
-
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
Score: 0.079
-
Controlled-release Sinemet. Neurology. 1987 Sep; 37(9):1567-8.
Score: 0.075
-
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology. 1987 May; 37(5):875-8.
Score: 0.073
-
Sinemet skin rash. Clin Neuropharmacol. 1984; 7(1):107-8.
Score: 0.058
-
Skin rash associated with Sinemet 25/100. N Engl J Med. 1983 Dec 01; 309(22):1387-8.
Score: 0.058
-
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
Score: 0.052
-
Parkinson's disease. Clin Neuropharmacol. 1999 Jul-Aug; 22(4):184-91.
Score: 0.042
-
Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep; 51(3):811-4.
Score: 0.040
-
Highlights of the North American and European experiences. Neurology. 1998 May; 50(5 Suppl 5):S15-6.
Score: 0.039
-
The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
Score: 0.037
-
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
Score: 0.036
-
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993 Sep; 43(9):1698-703.
Score: 0.028
-
Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
Score: 0.017
-
The pharmacology of olivopontocerebellar atrophy. Adv Neurol. 1984; 41:143-8.
Score: 0.015
-
Animal models of tardive dyskinesia: their use in the search for new treatment methods. Mod Probl Pharmacopsychiatry. 1983; 21:5-20.
Score: 0.014
-
Drug-induced asterixis in Parkinson disease. Neurology. 1982 May; 32(5):553-5.
Score: 0.013
-
Weekly drug holiday in Parkinson disease. Neurology. 1981 Nov; 31(11):1460-2.
Score: 0.012
-
Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures. Exp Neurol. 1991 Oct; 114(1):28-34.
Score: 0.006
-
The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
Score: 0.005
-
Pergolide mesylate: four years experience in Parkinson's disease. Adv Neurol. 1987; 45:547-9.
Score: 0.004
-
Pergolide mesylate and idiopathic Parkinson disease. Neurology. 1982 Oct; 32(10):1175-9.
Score: 0.003
-
Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig. Adv Neurol. 1982; 35:213-9.
Score: 0.003
-
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig. Life Sci. 1981 May 11; 28(19):2173-8.
Score: 0.003